Do ESR1 PvuII and XbaI polymorphisms affect estrogen therapy response?

The ESR1 PvuII (rs2234693) and XbaI (rs9340799) polymorphisms are key genetic variants that influence how target tissues respond to estrogen replacement therapy, particularly in postmenopausal women.

Clinical and physiological evidence

• Variable tissue response: Estrogen receptor alpha (ER-alpha) expression levels dictate target tissue sensitivity. Variations in these levels directly lead to distinct clinical outcomes during estrogen replacement.
• Bone mineral density (BMD): These polymorphisms are associated with baseline BMD and variable bone mass preservation during hormone therapy. Specifically, postmenopausal women carrying the rs9340799 AA and rs2234693 TT genotypes exhibit poorer BMD responses and diminished bone-protective benefits.

Mechanistic explanations

• Transcriptional modulation: Located in intron 1, these variants do not alter the amino acid sequence of the ER-alpha protein. Instead, they serve as regulatory markers that alter transcription factor binding and pre-mRNA splicing of the ESR1 gene.
• Expression changes: The XbaI A allele is associated with lower ESR1 mRNA expression. However, because these variants exhibit weak independent enhancer activity, some of their downstream signaling effects may also stem from linkage disequilibrium with other functional loci within the ESR1 gene.

Bottom line

• While ESR1 rs2234693 and rs9340799 polymorphisms plausibly modulate ER-alpha expression and downstream signaling through pre-mRNA splicing and transcriptional regulation, this genetic variation is scientifically established to drive clinically variable tissue and bone density responses during estrogen therapy.